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OBJECTIVE—Severalstudieshave suggestedthat HbA1clevelsmaypredict incident diabetes.
With new recommendations for use of HbA1c in diagnosing diabetes, many patients with HbA1c
results below the diagnostic threshold will be identiﬁed. Clinicians will need to categorize risk
for asubsequent diabeticdiagnosis insuchpatients.The objective of thisstudy wasto determine
the ability of HbA1c to predict the incidence of a diabetic diagnosis.
RESEARCH DESIGN AND METHODS—We performed a historical cohort study using
electronicmedicalrecorddatafromtwoDepartmentofVeteransAffairsMedicalCenters.Patients
(n=12,589) were identiﬁed with a baseline HbA1c ,6.5%between January2000and December
2001 and without a diagnosis of diabetes. Patients (12,375) had at least one subsequent follow-
up visit. These patients were tracked for 8 years for a subsequent diagnosis of diabetes.
RESULTS—During an average follow-up of 4.4 years, 3,329 (26.9%) developed diabetes.
HbA1c $5.0% carried a signiﬁcant risk for developing diabetes during follow-up. When com-
pared with the reference group (HbA1c ,4.5%), HbA1c increments of 0.5% between 5.0 and
6.4%hadadjustedoddsratiosof1.70(5.0–5.4%), 4.87 (5.5–5.9%),and 16.06 (6.0–6.4%)(P,
0.0001). Estimates of hazard ratios similarly showed signiﬁcant increases for HbA1c $5.0%.
A risk model for incident diabetes within 5 years was developed and validated using HbA1c, age,
BMI, and systolic blood pressure.
CONCLUSIONS—Theincidenceofdiabetesprogressivelyandsigniﬁcantlyincreasedamong
patientswithanHbA1c$5.0%,withsubstantiallyexpandedriskforthosewithHbA1c6.0–6.4%.
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bA1c is a well-established test to
track long-term glucose control
and the risk for developing micro-
vascular complications in patients with
diabetes (1). However, until recently,
HbA1c was not an accepted test for diag-
nosing diabetes because of concerns
about both lower speciﬁcity and sensitiv-
ity compared with fasting plasma glucose
(2). Anumberofthresholdvaluesthatrelate
HbA1ctoadiabeticdiagnosishavebeenpro-
posed in the past (3–7), but none were
broadly adopted. A recent report by an
International Expert Committee (8) pro-
posed that HbA1c $6.5% on two repeated
tests may be used to diagnose diabetes.
These recommendations were subsequently
accepted by the American Diabetes Associa-
tion (9). Implementation of the recommen-
dations will increase the number and
frequencyofHbA1ctestsobtainedinpatients
at risk for diabetes.Indeed,the ExpertCom-
mitteeraisedconcernsabouthowtoidentify
and manage higher risk individuals, as there
is yet no accepted HbA1c threshold value for
initiating preventive strategies.
Evidencesuggeststhatclinicianshave
been using HbA1c in the evaluation of pa-
tients without known diabetes in the ab-
sence of clearly accepted threshold values
for establishing a diagnosis. As an exam-
ple, in the Veterans Health Administra-
tion (VHA) in ﬁscal years 2006 and 2007
there were .500,000 patients without a
prior diagnosis of diabetes who had
HbA1c tests—representing 37 and 39%
of all patients having an HbA1c test per-
formed in those years (P.R.C., unpub-
lished observations).
To better understand the relationship
between HbA1c levels and the subsequent
risk of diagnosed diabetes, we identiﬁed
a cohort of patients without diabetes
in whom an HbA1c was obtained and
tracked these individuals for up to 8 years
for evidence of a diabetic diagnosis. We
hypothesized that a baseline HbA1c level
has predictive information for the future
development of diabetes and can be used
to risk stratify patients. Our data conﬁrm
the continuum of risk associated with
increasing levels of HbA1c and also
identify a HbA1c threshold value, below
which the risk is nominal.
RESEARCH DESIGN AND
METHODS
Study population
This historical cohort study included
12,589 patients at two Department of
Veterans Affairs (VA) Medical Centers
who had at least one HbA1c test ,6.5%
between 1 January 2000 through 31 De-
cember 2001 (baseline HbA1c). Institu-
tional review board approval was
obtained at both study sites before initiat-
ing the study.
Patient records were evaluated for
12 months before the baseline HbA1c to
assure that they had at least one ambula-
tory care visit, no HbA1c $6.5%, and no
diagnosis of diabetes. A diagnosis of dia-
beteswasdeﬁnedas:atleastoneinpatient
diagnosis of diabetes mellitus (ICD-9
code of 250.*), two or more outpatient
diagnoses of diabetes mellitus (ICD-9
code of 250.*), or a prescription for any
medication used in diabetic treatment.
This method to ascertain diabetic status
has been previously validated within the
ccccccccccccccccccccccccccccccccccccccccccccccccc
From the
1Department of Veterans Affairs Medical Center, Tampa, Florida; the
2Department of Epidemiology
andBiostatistics,CollegeofPublicHealth,UniversityofSouthFlorida,Tampa,Florida;the
3Departmentof
Pathology and Cell Biology, College of Medicine, University of South Florida, Tampa, Florida; the
4VA
Boston Healthcare System, Boston, Massachusetts; and the
5Department of Medicine, Harvard Medical
School, Boston, Massachusetts.
Corresponding author: Paul R. Conlin, paul.conlin@va.gov.
Received 1 April 2010 and accepted 19 December 2010.
DOI: 10.2337/dc10-0625
Theviewsexpressedinthisarticlearethoseoftheauthors.Thecontentofthisarticledoesnotnecessarilyreﬂect
thepositionandpolicyoftheUnitedStatesFederalGovernment,nordoesitnecessarilyrepresenttheviews
oftheDepartmentofVeteransAffairs.Noofﬁcialendorsementshouldbeinferred.Allauthorshadfullaccess
toallofthedatain thestudyand takeresponsibilityfortheintegrityofthedataandtheaccuracyofthedata
analysis.Thesponsorshadnoroleinthedesignandconductofthestudy;collection,management,analysis,
and interpretation of data; and preparation, review, or approval of the article.
© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited,theuseiseducationalandnotforproﬁt,andtheworkisnotaltered.Seehttp://creativecommons.org/
licenses/by-nc-nd/3.0/ for details.
610 DIABETES CARE, VOLUME 34, MARCH 2011 care.diabetesjournals.org
Epidemiology/Health Services Research
ORIGINAL ARTICLEVA (10). Participants with more than one
HbA1c test during the baseline period had
their ﬁrst test result used as the baseline.
Patients were requiredtohaveatleast one
ambulatory care visit at any time during
the follow-up period (from date of base-
line HbA1c test to 31 December 2008) or
until a diabetic diagnosis was made. After
the above exclusion criteria were applied,
12,375 patients were classiﬁed without
diabetes and were entered into the follow-
up period. The period of follow-up for
a given patient varied based on when
they had clinic visits during the follow-
up period.
Data were abstracted electronically
from the patients’ medical records. Infor-
mation was collected on outpatient clinic
visits, admissions, vital signs, outpatient
prescriptions, comorbid diagnoses, pa-
tient demographics, and laboratory tests.
Because our clinical laboratories do not
label glucose measurements as fasting or
nonfasting, we recorded glucose levels
obtained between 0600 and 1100 h as a
proxy for the fasting state. The ICD-9
codes used for the comorbid conditions
were as follows: cardiovascular disease
(CVD) (coronary heart disease 410–414;
stroke430–438;heartfailure428;cardiac
arrest 427.1, 472.4, 427.5; inﬂammatory
heart disease 429.01, 429.1, 420–425;
and hypertension 401–405). Race and
ethnicity were self-reported by patients.
The study end point was whether a diag-
nosisofdiabetesmellitusoccurredduring
the follow-up period.
During the study, both facilities used
the same methodology for measuring
HbA1c levels, which used a nonporous
ion-exchange high-performance liquid
chromatography to separate HbA1c from
other hemoglobin fractions and is certi-
ﬁed by the National Glycohemoglobin
Standardization Program. This method is
fairly immune to the presence of hemoglo-
binopathies or carbamylated hemoglobin
as a result of high urea concentrations.
Abnormal concentrations of hemoglo-
bins that may falsely elevate HbA1c are
clearly recognized.
Statistical analysis
The distribution of baseline HbA1c levels
was analyzed using univariate procedures
and stratiﬁed into ﬁve groups (1): ,4.5%
(2), 4.5–4.9% (3), 5.0–5.4% (4), 5.5–
5.9% (5), and 6.0–6.4%. The lowest
group, with HbA1c ,4.5%, was treated
as the reference group and all other
groups were compared with the reference
for risk calculation.
Data were analyzed using SAS 9.1
(SASInstitute,Cary,NC).Descriptivesta-
tistics were conducted on the study sam-
ple at baseline: median and range were
calculated for the continuous variables;
frequencyandproportionwerecalculated
for the categorical variables. The study
also comparedthebaselinecharacteristics
for patients who developed diabetes with
patients who did not develop diabetes
in the follow-up period. The nonpara-
metric Wilcoxon rank-sum test was used
to compare medians for continuous var-
iables, and the x
2 test was used to com-
pare proportionsfor categoricalvariables.
Given the large sample size, a P value of
,0.0001wasusedtodeterminestatistical
signiﬁcance. Both logistic regression
models and Cox proportional hazards
models were used to compare the risk of
developing diabetes with baseline HbA1c
level as the main effect (HbA1c ,4.5% as
reference group). Based on the univariate
results, a stepwise selection method (us-
ing an a of 0.05) was used for further
evaluation of the confounders in the mul-
tiple logistic regression. Both unadjusted
odds ratio/hazard ratio and multivariable
adjusted odds ratio/hazard ratio were cal-
culated. The Kaplan–Meier method was
used to calculate survival probability
withtime,andadiabeticeventprobability
versus time plot was developed and strat-
iﬁed by baseline HbA1c groups. All of the
12,375 patients were included in the sur-
vival analysis, including those patients
who died before developing diabetes.
Date of entry was the date on which the
initial HbA1c measurement was obtained.
For those patients who died, we used
their date of death as the censor time.
For patients who survived without devel-
oping diabetes, we used the last visit date
as their censor time in the survival analy-
sis calculation.
We also developed a risk model for
predicting the 5-year incidence of diabe-
tes using logistic regression. The 5-year
incidence of diabetes was deﬁned as any
patient who developed diabetes within
the 5-year period after the baseline HbA1c
test, and patients who did not develop di-
abetes within the 5-year period were used
as the control group. A simple risk model
was developed using baseline HbA1c as
the only predictor, and a multivariable
model was developed using baseline
HbA1c, age, BMI, and systolic blood pres-
sure (SBP) as predictors. The areas under
the two receiver operating characteristic
(ROC) curves (indicated by C statistic)
were compared using nonparametric
approaches (11). Finally, risk-calculating
equations were developed from the above
ﬁndings.
RESULTS—There were 12,589 indi-
viduals eligible for the study by having
an HbA1c test during the baseline period;
214 (1.7%) did not visit the clinic during
thefollow-upperiodandwerelosttofollow-
up, leaving 12,375 in the study popu-
lation. Baseline characteristics of the
12,375 individuals, including those who
developed diabetes during follow-up, are
shown in Table 1. Individuals were pre-
dominantly white men (95.4% men and
67.5% whites) with a median age of 65.9
(range 18.5– 101.5. Comparison of the
demographics and clinical characteristics
between these individuals and the 214
who had no follow-up visits showed no
signiﬁcant differences with regard to
HbA1c, age, glucose, SBP, creatinine, esti-
mated glomerular ﬁltration rate (eGFR),
sex, and presence of cardiovascular dis-
ease. Those lost to follow-up were signiﬁ-
cantlylower withregard todiastolicblood
pressure, albumin, BMI, and presence of
hypertension.
During an average follow-up of 4.4
yearsandwithanaverageof140(SD194)
ambulatory care visits, 26.9% developed
diabetes. The criteria by which diabetes
was diagnosed were: outpatient codes
(59.9%), inpatient codes (5.2%), and
new diabetes medication (34.9%). Blood
pressure, BMI, glucose, serum creatinine,
prevalent cardiovascular disease, and hy-
pertension were signiﬁcantly higher (P ,
0.0001) in patients who developed diabe-
tes. During the study period, there was a
progressive decline in the number and
percentage of individuals with clinic en-
counters in a given year. In the last year
of the study period, 6,997 (56.5%) indi-
viduals had one or more clinic visits,
2,671 (21.6%) patients had no clinic vis-
its,and2,707(21.9%)haddiedduringthe
8 years of follow-up.
Logistic regression was used to com-
pare the groups for risk of developing
diabetes in the follow-up period (Table 2).
When compared with the reference
HbA1c group (,4.5%), the group with
HbA1c 4.5–4.9% was not signiﬁcantly dif-
ferent,whereasriskofdevelopingdiabetes
increased steadily for the higher HbA1c
groups ($5.0%). The point estimates for
unadjusted odds ratios were 1.57 for
HbA1c 5.0–5.4%, 4.54 for HbA1c 5.5–
5.9%,and14.93forHbA1c6.0–6.4%com-
pared with HbA1c ,4.5% (P , 0.0001).
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logistic regression showed similar trends
with slight differences in point estimates
and95%conﬁdenceintervals.Weassessed
whether the number of outpatient visits
affected a diagnosis of diabetes but found
that it did not contribute to model ﬁta n d
was not included in the logistic regression
model.
Table 3 shows the results from the
Cox proportional hazards models. Esti-
mates of hazard ratios showed similar
patterns as the odds ratio estimates with
logisticregression.Nosigniﬁcantdifference
was detected between the reference group
and those with HbA1c 4.5–4.9%, but the
hazard ratio increased signiﬁcantly begin-
ning with HbA1c $5.0% (P , 0.0001),
with higher baseline HbA1c associated
with higher risk.
We analyzed event probability (i.e.,
developing diabetes) during the follow-
up period (Fig. 1) differentiated by base-
line HbA1c. Similar to our other analyses,
the curves for incident diabetes in those
with baseline HbA1c ,5.0% intertwined,
whereasthosewithhigherbaselineHbA1c
had signiﬁcantly higher probability of
developing diabetes during follow-up
(log-rank P value ,0.0001).
Risk models for a diabetic diagnosis
over 5 years were developed using HbA1c
alone (model 1) and a multivariable
model using HbA1c,a g e ,B M I ,a n dS B P
as predictors (model 2). For each pre-
dictor, a quadratic term was added into
the model because of nonlinear associa-
tion with risk (indicated by signiﬁcant P
values associated with quadratic terms).
For model 1, the area under the ROC
curve = 0.7543 (95% conﬁdence interval
0.7429–0.7657), and for model 2, the
Table 1—Baseline characteristics of study sample
All subjects Diabetes Nondiabetes P value Odds ratio (95% CI)
n 12,375 3,329 9,046
Age (years) 65.9 (18.5–101.5) 65.8 (26.1–90.5) 65.9 (18.5–101.5) 0.7759
Blood pressure (mmHg)
Systolic 139 (67–248) 141 (84–248) 138 (67–245) ,0.0001
Diastolic 77 (50–126) 78 (50–126) 76 (50–126) ,0.0001
BMI (kg/m
2) 29.0 (10.0–50.0) 30.0 (10.0–50.0) 28.0 (11.0–50.0) ,0.0001
Glucose (mg/dL) 107 (42–198) 118 (49–199) 101 (31–198) ,0.0001
Albumin (mg/dL) 4.1 (1.2–5.5) 4.0 (2.2–5.3) 4.1 (1.2–5.5) 0.0029
Creatinine (mg/dL) 1.0 (0.2–12.0) 1.0 (0.4–8.9) 1.0 (0.2–12.0) ,0.0001
eGFR (mL/min) 78.3 (4.5–197.5) 77.5 (6.3–189.0) 78.6 (4.5–197.5) ,0.0001
Sex ,0.0001 1.30 (1.06–1.59)
Men 11,805 (95.4) 3,202 (96.2) 8,603 (95.1)
Women 570 (4.6) 127 (3.8) 443 (4.9)
Ethnicity ,0.0001
Hispanic 323 (2.6) 138 (4.2) 185 (2.0)
Non-Hispanic 7,383 (59.7) 2,326 (69.9) 5,057 (55.9)
Unknown 4,669 (37.7) 865 (26.0) 3,804 (42.1)
Race ,0.0001
Black 712 (5.8) 208 (6.3) 504 (5.6)
White 8,351 (67.5) 2,337 (70.2) 6,014 (66.5)
Other 171 (1.4) 61 (1.8) 110 (1.2)
Unknown 3,141 (25.4) 723 (21.7) 2,418 (26.7)
Cardiovascular disease 3,911 (31.6) 1,147 (34.4) 2,764 (30.6) ,0.0001 1.19 (1.10–1.30)
Hypertension 7,251 (58.6) 2,199 (66.1) 5,052 (55.8) ,0.0001 1.54 (1.43–1.67)
eGFR ,60 mL/min 2,329 (18.8) 639 (19.2) 1,690 (18.7) 0.5176 1.03 (0.93–1.14)
Data are median (range) or n (%) unless otherwise indicated. P value and odds ratio compare both diabetic and nondiabetic groups.
Table 2—Risk comparison by logistic regression for developing diabetes according to baseline HbA1c groups
HbA1c groups
P trend 1( ,4.5) 2 (4.5–4.9) 3 (5.0–5.4) 4 (5.5–5.9) 5 (6.0–6.4)
N 519 1,918 4,416 3,663 1,859 —
Incident diabetes mellitus 53 190 668 1,248 1,170 —
Unadjusted odds ratio 1.00 0.97 1.57 4.54 14.93 ,0.0001
95% CI — 0.70–1.33 1.17–2.11 3.39–6.09 11.07–20.14
Multivariable-adjusted odds ratio* 1.00 1.01 1.70 4.87 16.06 ,0.0001
95% CI — 0.70–1.45 1.21–2.36 3.49–6.79 11.40–22.65 —
*Adjusted forage, sex, ethnicity (Hispanic or Latino, not Hispanic or Latino, or unknown), race (black, white,other, or unknown), BMI,and systolic blood pressure.
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Role of HbA1c in predicting diabetesarea under the ROC curve = 0.7791 (95%
conﬁdence interval: 0.7687–0.7896).
Comparison of the two areas showed sig-
niﬁcant improvement of the predict-
ability of model 2 (P value ,0.0001).
The Hosmer and Lemeshow Goodness-of-
Fit P value was 0.2827 for model 2, indi-
cating good model ﬁt.
Based on the above ﬁndings, we de-
veloped risk calculating equations as fol-
lows:
Odds ¼ expð20:459526:8111   HbA1c
þ0:7956   HbA1c
2
þ 0:1767   Age20:00144   Age2
þ 0:2372   BMI20:00281   BMI2
þ 0:0330   SBP20:00009   SBP2Þ
(1)
Probability ¼ odds/ð1 þ oddsÞ (2)
whereHbA1cishemoglobinHbA1cinper-
centage, age is indicated in years, BMI is
measured in kg/m
2, and SBP is indicated
in mmHg. The ﬁrst equation calculates
the odds of developing diabetes mellitus
in 5 years, and the second equation cal-
culates the probability of developing di-
abetes mellitus in 5 years using the result
from Eq. 1.
CONCLUSIONS—We found that
baseline HbA1c was signiﬁcantly predic-
tive of the subsequent development of a
diagnosis of diabetes over an 8-year pe-
riod. The risk of developing diabetes in-
creased progressively at HbA1c levels
$5.0%, with an odds ratio exceeding 16
inthose with HbA1c 6.0–6.4%.Thislatter
group had a cumulative incidence of di-
abetes approaching 80%. Not surpris-
ingly, signiﬁcant predictors for diabetes
incidence included clinical parameters,
such as blood pressure, BMI, serum cre-
atinine, prevalent cardiovascular disease,
and hypertension. From these data, we
also developedrisk–calculatingequations
for determining the probability of devel-
oping a diabetic diagnosis within 5 years.
We believe that these data will inform
clinicians on how to risk–stratify individ-
uals who are screened for diabetes using
HbA1c but whose levels do not reach the
recommended diagnostic threshold of
$6.5%.
Several studies have evaluated HbA1c
as a predictor of subsequent diabetes or
as a tool to diagnose treatment-requiring
diabetes (3–7,12–19). A number of
threshold values have been previously
proposed for diagnosing diabetes, such
as $7.0% (4,7), $6.5% (13), .2S D
above the normal mean (i.e., .6.1%)
(6). In addition,a number of HbA1c levels
have also been proposed to identify indi-
viduals at risk for diabetes (i.e., prediabetes),
such as 6.1–6.9% [7], 6.0–6.4% [8], or
5.7–6.4% [1]. The implementation of
newguidelinesfordiagnosingdiabetesus-
ingHbA1cwillhelpstandardizethewayin
which clinicians apply results from this
test. However, there remains uncertainty
on how to classify and whether to inter-
veneinindividualswhose levels fallbelow
this threshold.
There isgrowingevidence that HbA1c
may not only predict diabetes but also
cardiovascular disease and death (12–
19). Among women without diabetes,
HbA1c levels were signiﬁcantly associated
with both, although the presence of other
cardiovascularriskfactorsmaycontribute
additionally to this risk (15,16). Selvin
et al. (18) showed that, in a community-
based population, HbA1c was signiﬁ-
cantly associated with risk of developing
both diabetes and cardiovascular disease
independent of fasting glucose levels. As
withourresults,theyshowedthatlevels
$6.0% carried the greatest risk. There-
fore, these results strongly suggest that
individuals with HbA1c levels $6.0%
should be targeted for prevention strat-
egies to reduce not only incident diabe-
tes but possibly also cardiovascular
disease.
Table 3—Risk comparison by Cox proportional hazards model for developing diabetes according to baseline HbA1c groups
HbA1c groups
P trend 1( ,4.5) 2 (4.5–4.9) 3 (5.0–5.4) 4 (5.5–5.9) 5 (6.0–6.4)
Unadjusted hazard ratio 1.00 0.90 1.41 3.69 9.62 ,0.001
95% CI — 0.66–1.22 1.07–1.87 2.80–4.86 7.30–12.67
Multivariable-adjusted hazard ratio* 1.00 0.92 1.42 3.54 8.71 ,0.001
95% CI — 0.66–1.27 1.05–1.92 2.63–4.75 6.47–11.73 —
*Adjusted for age, sex, ethnicity, race, BMI, and systolic blood pressure.
Figure 1—Plot of diabetes event probability against follow-up time, differentiated by baseline
HbA1c. The curves for the two lowest groups substantially overlap, but groups with HbA1c$5.0%
have signiﬁcantly higher probability of developing diabetes during the 8-year study period (log-
rank P value ,0.0001).
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Cheng and AssociatesMany clinicians have been attracted
to using HbA1c as a screening test for di-
abetes since the test reﬂects longer-term
glucose control, does not require fasting,
has less day-to-day biologic variability,
and is a well-accepted marker of risk of
long-term microvascular complications
(20).Suchusageisevidencedbyourlarge
cohort of patients in whom HbA1c levels
were obtained in patients without a diag-
nosisofdiabetes.However,priorguidelines
discouraged use of HbA1c for diagnosing
diabetes, largely as a result of standardiza-
tion and reproducibility issues that pre-
cluded its use in such broad settings.
Current instrumentation and standardiza-
tion methods (21) aligned with the Diabe-
tes Control and Complications Trial have
abrogated most of these issues. Such evi-
dence was cited by the International Ex-
pert Committee (8) and afﬁrmed by the
American Diabetes Association(9) intheir
acceptance of HbA1c for screening and
diagnosis.
Signiﬁcant strengths of this study are
its large population drawn from two VA
medical centers in different geographic
regions, the ability to query a robust elec-
tronic medical record for clinical and de-
mographic factors, and patient follow-up
for up to 8 years. Important limitations
include the largely white men and older
population, the reliability of the admin-
istrative data set, and the selection and
ascertainment bias related to patients for
whom HbA1c testing was performed. It is
possible that HbA1c tests were performed
in patients who were preselected for the
presence of other known risk factors for
diabetes. Such selective screening might
bias our results toward showing a higher
risk of developing diabetes for a given
HbA1c level. To address this, our analyses
controlled for many known risk factors
and helped identify those factors thatcon-
tribute signiﬁcantly with HbA1c in pre-
dicting risk of diabetes. To account for
the possible confounding effects from
sex and age, we incorporated these two
variables with several other known risk
factors in our 8-year follow-up models to
calculate odds ratios (hazard ratios) based
on baseline HbA1c. In our 5-year risk pre-
diction model, the sex variable did not
provide signiﬁcant contribution to the
predictability of the model.
Other factors may limit the general-
izability of our ﬁndings. We did not have
informationontheprevalenceofsmoking
inthestudypopulation,whichisaknown
risk factor for diabetes (22) and is higher
among veterans than nonveterans (23).
This might tend to inﬂate the risks of
diabetes that we observed. Another po-
tential bias is that a greater amount of
medical care (e.g., increased number of
clinic visits) might associate with a higher
numberof diabetes casesascertaineddur-
ing the study. We adjusted for the num-
ber of medical visits but did not ﬁnd that
this signiﬁcantly inﬂuenced the models.
In addition, there were 214 individuals
initially eligible to participate but who
were lost to follow-up. Demographic
and clinical characteristics of these indi-
viduals were quite similar to the remain-
ing cohort. Those areas in which they
differed werein adirectionthatparalleled
those who did not develop diabetes dur-
ing follow-up. Although their absence
from the cohort can introduce bias in
the ascertainment of both exposure and
outcome, we believe that both the small
number as well as the characteristics of
these individuals makes it unlikely that
this substantially affected the reported in-
cidence of diabetes. Finally, we identiﬁed
diagnosed diabetes based on medical re-
cord evidence that the patient was actu-
ally diagnosed by a clinician and/or
treated with a diabetes medication. These
criteria would exclude patients who have
an unrecorded but true diagnosis of dia-
betes for whom no medications were
prescribed, which could lead to an
underestimation of the true risk of devel-
oping diabetes. However, the number of
such patients should be small because of
our use of multiple variables to establish a
diagnosis of diabetes and the extended
follow-up period.
In summary, we have characterized
the risk of developing diabetes in patients
without a diagnosis of diabetes who had a
baseline HbA1c levels ,6.5%. These data
showaprogressiveriskfordevelopingdi-
abetes when HbA1c is $5.0%, with nom-
inal risk below that level. We generated a
risk calculator using HbA1c and other
clinical data that estimate the 5-year risk
of developing diabetes. Because clinicians
implement HbA1c testing to screen for di-
abetes, these data may be used to help
identify the risk of incident diabetes
among individuals with HbA1c levels
,6.5%.
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